Document Detail


Comparison of the effect of aminophylline and low PEEP vs. high PEEP on EGF concentration in critically ill patients with ALI/ARDS.
MedLine Citation:
PMID:  15811166     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Acute respiratory distress syndrome (ARDS) remains a serious, often fatal, condition, despite progress in modern critical care treatment. Cytokines play important roles in the pathogenesis of the syndrome, although their roles in the evaluation and outcome have not been clearly elucidated yet. OBJECTIVES: We tested whether serum concentration of epidermal growth factor (EGF), as one of the important inflammatory mediators, changes with time and administration of mechanical ventilation and aminophylline. PATIENTS AND METHODS: Thirty patients [mean (SD): age = 56.6 (17.4) years] with ARDS were enrolled. After diagnosis based on inclusion and exclusion criteria, the patients were intubated and mechanically ventilated. Two hours after ventilation with definite positive end-expiratory pressure (PEEP), aminophylline with a specific dose was started. Serum samples were obtained at five time points of 0, 2, 2.5, 4 and 8 h post-starting PEEP. RESULTS: Serum EGF concentration decreased after mechanical ventilation with PEEP (P < 0.05). The serum EGF concentrations 8 h after intervention was statistically lower in the low PEEP group than in the high PEEP group. The Acute Physiology and Chronic Health Evaluation (APACHE) Pi score and PaO2/FiO2 improved significantly after 8 h (P < 0.05). CONCLUSION: Beneficial effects of mechanical ventilation and aminophylline on APACHE Pi score and PaO2/FiO2 influence serum EGF levels. These findings may have relevance to the development of multisystem organ failure.
Authors:
P Salari; M Mojtahedzadeh; A Najafi; S Sadraie; K Bahaadini; M Moharreri; N Hadavand; M Abdollahi
Related Documents :
20509966 - Bedside measurement of changes in lung impedance to monitor alveolar ventilation in dep...
15329586 - Recruitment maneuvers after a positive end-expiratory pressure trial do not induce sust...
3893886 - Left ventricular geometry during positive end-expiratory pressure in dogs.
14707576 - Effects of cyclic opening and closing at low- and high-volume ventilation on bronchoalv...
3343736 - Selection of intestinal segments for bladder substitution: physical and physiological c...
11593376 - Mechanical ventilation during pregnancy using a helium-oxygen mixture in a patient with...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  30     ISSN:  0269-4727     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2005 Apr 
Date Detail:
Created Date:  2005-04-06     Completed Date:  2005-11-03     Revised Date:  2008-05-28    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  139-44     Citation Subset:  IM    
Affiliation:
School of Pharmacy and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
APACHE
Aminophylline / administration & dosage,  blood,  therapeutic use*
Critical Illness*
Epidermal Growth Factor / blood*,  drug effects
Female
Humans
Injections, Intravenous
Intensive Care Units
Male
Middle Aged
Outcome Assessment (Health Care) / methods,  statistics & numerical data
Oxygen / analysis,  blood,  physiology
Partial Pressure
Patient Selection
Positive-Pressure Respiration / methods*
Respiratory Distress Syndrome, Adult / blood*,  drug therapy,  mortality
Time Factors
Chemical
Reg. No./Substance:
317-34-0/Aminophylline; 62229-50-9/Epidermal Growth Factor; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-bli...
Next Document:  Adoption of celecoxib and rofecoxib: a nationwide database study.